Ophthalmic Patents (Class 514/912)
  • Patent number: 10087151
    Abstract: The present invention relates to compounds including but not limited to of any one of formulas Ia, Ib, IIa, IIb, IIIa, IIIb, and IV to VI, VIIa, VIIb, VIIIa, VIIIb and VIIIc as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: October 2, 2018
    Assignee: THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE
    Inventors: Andrey S. Tsvetkov, Steven M. Finkbeiner, Michael A. Pleiss, Robert Greenhouse
  • Patent number: 9023898
    Abstract: A flushing solution is described which is suitable for use in surgical, in particular ophthalmological, operations and which contains a non-Newtonian fluid. The use of such a flushing solution is also described. The flushing solution can be used as an intraoperative instrument, particularly as an instrument for manipulating intraocular structures such as retina.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: May 5, 2015
    Assignee: Fluoron GmbH
    Inventors: David Wong, Christian Lingenfelder
  • Patent number: 9018202
    Abstract: Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine, certain of its metabolites, clozapine, and n-desmethyl clozapine.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: April 28, 2015
    Assignee: Allergan, Inc.
    Inventors: Jyotirmoy Kusari, Sheila X. Zhou, Mingting Tian, Edwin U. Padillo, Sandhya S. Rao, Daniel W. Gil, Larry A. Wheeler
  • Patent number: 9017725
    Abstract: Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: April 28, 2015
    Assignee: Aurinia Pharmaceuticals Inc.
    Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Ulrich M. Grau
  • Patent number: 9006214
    Abstract: The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles, aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: April 14, 2015
    Assignee: Altaire Pharmaceutical, Inc.
    Inventor: Assad S. Sawaya
  • Patent number: 8979809
    Abstract: A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: March 17, 2015
    Assignee: Ocularis Pharma, LLC
    Inventor: Gerald Horn
  • Patent number: 8980957
    Abstract: The subject invention relates to a method of preparing a biocompatible polymer comprising epsilon-linked L-lysine having free alpha-amino and carboxy functions. The invention further encompasses the resulting biocompatible polymer and articles made from the polymer, in particular contact and intraocular lenses.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: March 17, 2015
    Assignee: CIS Pharma AG
    Inventors: Rolf Schäfer, Hans Hitz
  • Patent number: 8969307
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8969385
    Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: March 3, 2015
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Keith Johnson
  • Patent number: 8969306
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8962691
    Abstract: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 24, 2015
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, David A. Saperstein
  • Patent number: 8961993
    Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 24, 2015
    Assignees: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Michael Belkin, Aviv Shaish, Dror Harats, Ygal Rotenstreich
  • Patent number: 8946281
    Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 3, 2015
    Assignee: Allergan Sales, LLC
    Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
  • Patent number: 8940318
    Abstract: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: January 27, 2015
    Assignees: Seed Co., Ltd., Senju Pharmaceutical Co., Ltd.
    Inventors: Takao Sato, Toru Matsunaga, Aya Ichinokawa, Osamu Sakai
  • Patent number: 8912236
    Abstract: The present invention relates to development of efficacious pharmaceutical implant compositions comprising an active agent in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: December 16, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Malay Ghosh, Adrian Sauceda
  • Patent number: 8906950
    Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 9, 2014
    Assignee: Allergan Sales, LLC
    Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
  • Patent number: 8889735
    Abstract: The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian subject. The present invention also relates to a composition for treating asthenopia, accommodative dysfunction or ocular pain comprising a specific prostaglandin compound.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: November 18, 2014
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 8865776
    Abstract: The use of low molecular weight amino alcohols in ophthalmic compositions is described. These compounds have been found to enhance the efficacy of anti-microbial preservatives.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: October 21, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Bahram Asgharian
  • Patent number: 8853251
    Abstract: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: October 7, 2014
    Assignee: Allergan, Inc.
    Inventors: Mohammed I. Dibas, Daniel W. Gil, Ken Chow, Liming Wang, Michael E. Garst, John E. Donello
  • Patent number: 8853268
    Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: October 7, 2014
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Patent number: 8829037
    Abstract: The present disclosure describes compositions which improve visual acuity and to methods for their use.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: September 9, 2014
    Inventor: Anant Sharma
  • Patent number: 8815946
    Abstract: Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is to a subject's cornea, such as a wound resulting from refractive surgery. In one embodiment, the amide or ester of an alpha-ketoalkanoic acid is ethyl pyruvate.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: August 26, 2014
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Weixang Dai, James L. Funderburgh, Joel S. Schuman, Nirmala SundarRaj
  • Patent number: 8791158
    Abstract: The present invention includes methods for treating Meibomian gland dysfunctions. The invention also includes methods for improving tear lipid composition, for treating abnormal Meibomian gland secretion and for normalizing Meibomian gland secretions.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: July 29, 2014
    Assignee: GTX, Inc.
    Inventors: James T. Dalton, Jeetendra Eswaraka
  • Patent number: 8771715
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: July 8, 2014
    Assignee: Sarcode Bioscience Inc.
    Inventors: Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Patent number: 8765758
    Abstract: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: July 1, 2014
    Assignee: Eye Therapies LLC
    Inventor: Gerald Horn
  • Patent number: 8765787
    Abstract: Self-preserving ophthalmic formulations containing norketotifen and methods of making the same and the use thereof in patients suffering from xerophthalmia are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof, self-preserving topical ophthalmic formulations containing norketotifen, free from any added preservative.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 1, 2014
    Assignee: Bridge Pharma, Inc.
    Inventors: A.K. Gunnar Aberg, Keith Johnson
  • Patent number: 8758776
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 24, 2014
    Assignee: Sarcode Bioscience Inc.
    Inventors: Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Patent number: 8754029
    Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: June 17, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Kazuhiro Fukushima
  • Patent number: 8741930
    Abstract: Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: June 3, 2014
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Keith Johnson
  • Patent number: 8729128
    Abstract: Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: May 20, 2014
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Nicolas G. Bazan, Jiu-Cheng He, Haydee E. P. Bazan
  • Patent number: 8722666
    Abstract: A drug for sedating a patient, and especially a smoker, during eye surgery. The drug includes a sedative such as midazolam in a mix with nicotine. The mixture is injected into the patient prior to the eye surgery.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: May 13, 2014
    Inventor: Walter J. Cukrowski
  • Patent number: 8722728
    Abstract: The present invention provides for compositions, medicaments, and methods for treating or alleviating the symptoms of dry eye syndrome or chronic dry eye. More specifically, the present embodiments provide for medicaments consisting of tocopherol or tocotrienol eyedrops. A single topical administration of tocopherol or tocotrienol eyedrops in the eyes of a subject suffering from dry eye alleviates symptoms for at least one day. In particular, the eyedrop medicament consists of ?-tocopheryl acetate; ?-tocopheryl acetate and about 0.5% aqueous component; or ?-tocopheryl acetate, about 2.5% tocopherol emulsifier, and about 20% to about 30% aqueous excipient.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: May 13, 2014
    Assignee: Ramscor, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood
  • Patent number: 8709515
    Abstract: The method comprises steps of: providing a nutraceutical including, in combination, 1.13 to 3 mg lutein and 18.8 to 51.2 mg omega fatty acids and 1.9 to 5.2 mg grape seed extract and 1.9 to 5.2 mg alpha lipoic acid; determining the weight of each dose of the components in the combination based upon an amount per kg body weight of the animal patients; and administering 1 dose of nutraceutical per day to animals suffering from ocular health issues including any degenerative retinal disease and diabetic cataracts and prior to and following cataract surgery for the diminishment and prevention of secondary cataracts.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 29, 2014
    Inventors: Carmen C. H. Colitz, Terri L. McCalla, Debra A. Smith
  • Patent number: 8710102
    Abstract: Compositions and methods for treating disorders of the outer retina with ?-adrenoceptor antagonists are disclosed.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: April 29, 2014
    Assignee: Novartis AG
    Inventors: Robert J. Collier, Jr., Michael A. Kapin, Louis DeSantis, Jr.
  • Patent number: 8691876
    Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: April 8, 2014
    Assignee: FXS Ventures, LLC
    Inventor: Francis X. Smith
  • Patent number: 8691289
    Abstract: The present invention relates to a method of treating an outer eye disorder selected from a cataract, neovascularization, keratitis, epithelium deficiency, or chronic opacity, by administering to the eye a composition comprising acidic electrolytic water. The present invention also relates to a stable acidic electrolyzed oxidizing water characterized by low conductivity, the presence of dissolved chlorine gas (Cl2), hypochlorous acid (HOCl) and chloride ions (Cl?), and by the presence of negligible quantities of hypochlorite ion (OCl?).
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: April 8, 2014
    Assignee: APR Nanotechnologies S.A.
    Inventors: Yongge Chen, Roberto De Noni
  • Patent number: 8691874
    Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 8, 2014
    Assignee: Kato Pharmaceuticals, Inc.
    Inventors: Vicken H. Karageozian, David Castillejos, John Park
  • Patent number: 8680078
    Abstract: Disclosed herein are stable formulations suitable for the treatment of glaucoma and ocular hypertension.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: March 25, 2014
    Assignee: Medivis SRL
    Inventors: Danilo Aleo, Sergio Mangiafico, Maria Grazia Antonietta Saita
  • Patent number: 8679511
    Abstract: An in-situ gel ophthalmic drug delivery system for estrogen containing an estrogen, a solubilizing and complexing agent, a humectant, a sorbic acid or sorbic acid based stabilizer, an optional chelating agent and gellan gum in the amount of about 0.1-0.5% w/v, optionally 0.1-0.3% w/v, of the composition.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: March 25, 2014
    Assignee: Duquesne University of the Holy Spririt
    Inventors: Moji Christianah Adeyeye, Vicki L. Davis, Uday K. Kotreka
  • Patent number: 8673937
    Abstract: Disclosed is a technique for preventing the decomposition of latanoprost (a thermally unstable substance) contained in an eye-drop solution to stabilize the eye-drop solution. Specifically disclosed is an eye-drop preparation comprising latanoprost and carteolol hydrochloride. By adding carteolol hydrochloride to an eye-drop solution containing latanoprost which is a thermally unstable substance and is likely to be adhered on the surface of a container, it becomes possible to prevent the decomposition of latanoprost in the eye-drop solution and also prevent the loss of latanoprost caused by the adsorption of latanoprost on the surface of a container.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: March 18, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yoshinao Onishi, Shinichi Ishikawa
  • Patent number: 8673280
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: March 18, 2014
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8668920
    Abstract: A method, device, and system for easier, consistent, and comfortable delivery of therapeutic agents to the front of the eye.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: March 11, 2014
    Assignee: HEK Development, LLC
    Inventor: Herbert Edward Kaufman
  • Patent number: 8669241
    Abstract: The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 11, 2014
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Mariyo Kato
  • Patent number: 8664180
    Abstract: Ophthalmic composition that includes 0.05% w/v to 2% w/v diglycine or a salt thereof; 0.01 ppm to 3 ppm poly(hexamethylene biguanide); 1 ppm to 10 ppm ?-[4-tris(2-hydroxyethyl)ammonium chloride-2-butenyl]poly[1-dimethylammonium chloride-2-butenyl]-?-tris(2-hydroxyethyl)ammonium chloride; and 0.1% w/v to 2% w/v of one or more boron buffering compounds.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: March 4, 2014
    Assignee: Bausch & Lomb Incorporated
    Inventors: Susan E. Burke, Erning Xia, Catherine A. Scheuer, Srini Venkatesh
  • Patent number: 8658624
    Abstract: The present invention relates to pharmacology, medicine, opthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 25, 2014
    Assignee: Mitotech SA
    Inventors: Vladimir P. Skulachev, Maxim V. Skulachev
  • Patent number: 8658633
    Abstract: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an ansamycin analog or heat shock protein 90 inhibitor, for example, 17-allylamino-17-demethoxygeldanamycin.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: February 25, 2014
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Vasiliki Poulaki, Joan W. Miller, Evangelos S. Gragoudas
  • Patent number: 8648107
    Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 11, 2014
    Assignee: Allergan Sales, LLC
    Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
  • Patent number: 8637544
    Abstract: The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: January 28, 2014
    Assignees: Senju Pharmaceutical Co., Ltd., Astellas Pharma Inc.
    Inventors: Chiho Yabuta, Fumiko Yano, Mitsuyoshi Azuma
  • Patent number: 8637070
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 28, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Patent number: 8633181
    Abstract: This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: January 21, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Suqin Guo